FILE – British Columbia Attorney General David Eby pauses while responding to questions after a court ruled that British Columbia cannot restrict oil shipments through its borders, in Vancouver, on Friday May 24, 2019. THE CANADIAN PRESS/Darryl Dyck

B.C. pleased with Oklahoma ruling in opioids case as it continues lawsuit

The untested suit alleges the companies falsely marketed opioids as less addictive than other pain drugs

British Columbia’s attorney general says he is pleased with the findings of a court in Oklahoma that found Johnson & Johnson and its subsidiaries helped fuel the state’s opioid crisis as it ordered the company to pay US $572 million, more than twice the amount another drug manufacturer agreed to pay in a settlement.

The province filed a proposed class-action lawsuit a year ago against dozens of pharmaceutical companies in a bid to recoup the health-care costs associated with opioid addiction.

The untested suit alleges the companies falsely marketed opioids as less addictive than other pain drugs and helped trigger an overdose crisis that has killed thousands since OxyContin was introduced to the Canadian market in 1996.

David Eby likened the aim of the lawsuit in British Columbia to the one in Oklahoma.

“The lawsuit we launched in 2018 holds pharmaceutical companies similarly accountable for the harm they have done to British Columbians and for the financial burdens they have placed on our health care system,” he alleged in a statement on Monday.

“Along with our recently enacted Opioid Damages and Health Care Costs Recovery Act, this measure is another example of the work that this government is undertaking every day to address the ongoing opioid crisis and build a better system of care and support for British Columbians.”

The civil claim filed by the B.C. government names the maker of OxyContin — Purdue Pharma Inc. — as well as other major drug manufacturers, and also targets pharmacies, alleging they should have known the quantities of opioids they were distributing exceeded any legitimate market.

None of the allegations contained in the civil claim has been proven in court.

A statement of defence from Purdue Pharma could not be found on the B.C. Supreme Court website on Monday, but in a previous statement the company said it followed all of Health Canada’s regulations, including those governing marketing. The company also says it has adhered to the code of ethical practices as a member of Innovative Medicines Canada, a pharmaceutical industry organization that works with governments, insurance companies and health-care professionals.

“Purdue Pharma (Canada) is deeply concerned about the opioids crisis, in British Columbia, and right across Canada,” the company said in a statement after B.C. filed its lawsuit.

“The opioids crisis is a complex and multi-faceted public health issue that involves both prescription opioids and, increasingly, illegally produced and consumed opioids, as indicated in Health Canada’s latest quarterly monitoring report. All stakeholders, including the pharmaceutical industry, have a role to play in providing practical and sustainable solutions.”

Earlier this year, the Ontario government said it plans to join B.C.’s proposed lawsuit.

In Oklahoma, Cleveland County District Judge Thad Balkman’s ruling followed the first state opioid case to make it to trial and could help shape negotiations over roughly 1,500 similar lawsuits filed by state, local and tribal governments consolidated before a federal judge in Ohio.

“The opioid crisis has ravaged the state of Oklahoma,” Balkman said before announcing the judgment. “It must be abated immediately.”

An attorney for the companies said they plan to appeal the ruling to the Oklahoma Supreme Court.

Before Oklahoma’s trial began May 28, the state reached settlements with two other defendant groups — a $270 million deal with Purdue Pharma and an $85 million settlement with Israeli-owned Teva Pharmaceutical Industries Ltd.

Oklahoma argued the companies and their subsidiaries created a public nuisance by launching an aggressive and allegedly misleading marketing campaign that overstated how effective the drugs were for treating chronic pain and understated the risk of addiction.

READ MORE: Fatal overdoses in B.C. drop 30% during first half of year

READ MORE: Canadian drug makers hit with $1.1B suit for pushing opioids despite risks

READ MORE: Health Canada tightens marketing requirements for opioid prescriptions

The Canadian Press


Like us on Facebook and follow us on Twitter.

Just Posted

Port Alberni’s newest street gets Nuu-chah-nulth name

Process prompts review of pre-approved names

EJ Dunn Elementary School celebrates playground

MLA Scott Fraser cuts official ribbon, climbs with kids at Port Alberni play space

Port Alberni students meet federal NDP leader Jagmeet Singh at rally

Singh posts trending video to TikTok, says reaching youth on their level is important

VIDEO: Saanich resident shocked when trespasser licks security camera, rummages through mail

‘I found the situation really bizarre,’ said the Gordon Head resident

Hundreds come out to meet federal NDP leader at Port Alberni rally

Pipelines, a coalition government and reconciliation among topics Jagmeet Singh covers

Environment Canada issues gale warnings for western Vancouver Island

Gale warnings in effect for most of Vancouver Island and west coast Mainland

BC Ferries crew member taken to hospital after getting struck by bow doors

Two sailings between Horseshoe Bay and Departure Bay were cancelled

Greta Thunberg meets with First Nations chief in Fort McMurray

Thunberg has turned her protest against climate change into a global movement

Canucks hang on for 3-2 win over Rangers in New York

Vancouver scores three times in first period

More beef products recalled due to possible E. coli contamination

The food safety watchdog has been investigating possible E. coli 0157:H7

B.C. VIEWS: How to get the best deal on your ICBC car insurance

ICBC slowly being dragged into the 21st century

Most Read